DEFA14A: Seres Therapeutics to Sell VOWST Business to Nestl Health Science for Up to $500 Million

Seres Therapeutics is selling its VOWST business to Nestl Health Science for an upfront payment and potential milestone payments, allowing Seres to focus on its pipeline and extend its cash runway.

Summary

• Seres Therapeutics has entered into an Asset Purchase Agreement with Nestl Health Science to sell its VOWST business.
• Seres will receive an upfront payment of $175 million, including a prepayment of a future commercial milestone payment and an equity investment, less approximately $20 million in settlement of net obligations.
• An additional $75 million in cash payments are due to Seres in 2025, contingent upon Seres compliance with transition obligations.
• Seres could receive up to $275 million in future commercial milestone payments based on VOWST net sales targets.
• Nestl will purchase $15 million of Seres common stock at $1.05 per share.
• Seres plans to use the proceeds to retire its debt obligations and advance its pipeline, including SER-155.
• Seres expects to reduce its workforce by more than one-third to streamline operations.
• The transaction is expected to close in the next 90 days, subject to shareholder approval and customary conditions.
• Seres anticipates its cash runway will extend into Q4 2025 based on existing cash, deal economics, and operating plans.
• Seres will support ongoing VOWST availability by providing transition services through the first quarter of 2025 and manufacturing support through the end of 2025.
• Seres will continue to share 50/50 in the profit and loss of the business through the end of 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While Seres is selling a key asset, the deal provides significant capital, extends the cash runway, and allows the company to focus on its pipeline. The potential for future milestone payments adds to the positive outlook.

Positives

• Seres will receive a significant cash infusion of $175 million upfront.
• The deal allows Seres to retire its debt obligations.
• The transaction extends Seres' cash runway into Q4 2025.
• Seres can focus on its pipeline and the development of SER-155 and other cultivated live biotherapeutic candidates.
• Nestl's equity investment in Seres common stock reflects confidence in the company's future.
• The potential for up to $275 million in future milestone payments based on VOWST net sales provides additional upside.
• Seres will continue to share 50/50 in the profit and loss of the business through the end of 2025.

Negatives

• Seres is selling its FDA-approved product, VOWST, which could limit future revenue potential.
• The deal is subject to shareholder approval, which introduces some uncertainty.
• Seres will reduce its workforce by more than one-third, which may impact employee morale and productivity.
• The receipt of installment payments in 2025 is contingent upon Seres' compliance with transition obligations.
• The $1.05 share price for Nestl's equity investment represents a 10% premium to the 30-day volume weighted average price prior to the announcement of the Memorandum of Understanding, which may not be viewed as a substantial premium by some investors.

Risks

• The transaction may not close within the expected timeframe or at all.
• Seres may not achieve the VOWST net sales targets required to receive the full $275 million in milestone payments.
• The transition of VOWST to Nestl may not be seamless, potentially impacting sales and profitability.
• Seres' pipeline candidates, including SER-155, may not be successful in clinical trials.
• Seres may face challenges in reducing its workforce and streamlining operations.
• The company's future success depends on its ability to develop and commercialize new therapeutics for medically vulnerable populations.

Future Outlook

Seres will focus on developing new therapeutics for medically vulnerable populations, leveraging its experience with cultivated live biotherapeutic candidates and the clinical and regulatory success of VOWST. The company's lead program, SER-155, is designed to prevent GI-derived infections and reduce the incidence of GvHD in patients undergoing allo-HSCT.

Management Comments

• 'This transaction provides meaningful capital to support Seres pipeline advancement and our focus on improving patient outcomes in medically vulnerable populations through the use of cultivated live biotherapeutics,' said Eric Shaff, President and Chief Executive Officer of Seres.
• 'We are proud of our accomplishments in bringing VOWST to the market as the first ever FDA-approved oral microbiome therapy with an outstanding efficacy and safety profile and now look forward to applying our approach to transform care in new patient groups,' said Eric Shaff, President and Chief Executive Officer of Seres.
• Mr. Shaff continued, 'We will use the capital from this transaction to strengthen our balance sheet, retire our existing debt facility, and advance our pipeline.'

Industry Context

The sale of VOWST to Nestl Health Science reflects the growing interest in microbiome-based therapies and Nestl's strategic focus on expanding its portfolio in this area. Seres' decision to focus on its pipeline and develop new therapeutics for medically vulnerable populations aligns with the broader trend of pharmaceutical companies prioritizing innovative therapies with high unmet medical needs.

Comparison to Industry Standards

• The deal structure, with a mix of upfront payments, milestone payments, and an equity investment, is common in the pharmaceutical industry for asset acquisitions.
• Comparable companies in the microbiome therapeutics space include Finch Therapeutics, 4D pharma and BiomX.
• The potential milestone payments of up to $275 million based on VOWST net sales are typical for products with significant commercial potential.
• The decision to reduce the workforce by more than one-third is a common cost-cutting measure following an acquisition or asset sale.

Stakeholder Impact

• Shareholders will benefit from the cash infusion and extended cash runway.
• Employees will be impacted by the workforce reduction.
• Patients will continue to have access to VOWST through Nestl Health Science.
• Suppliers and partners will need to adjust to the change in ownership of the VOWST business.
• Creditors will benefit from the retirement of Seres' debt obligations.

Next Steps

• Seres will seek shareholder approval for the proposed transaction.
• Seres will work to close the transaction within the next 90 days.
• Seres will use the proceeds to retire its debt obligations and advance its pipeline.
• Seres will continue to develop SER-155 and other cultivated live biotherapeutic candidates.
• Seres will provide transition services and manufacturing support to Nestl for VOWST.

Key Dates

Keywords

Seres Therapeutics, Nestl Health Science, VOWST, Asset Purchase Agreement, Microbiome, SER-155, Live Biotherapeutics, Acquisition, FDA Approval, Cash Runway